Newsfeeds Archive - Page 83 of 167

2 minute read

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) To IND-enabling Stage

September 6, 7:09 AM

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced today that its human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein, AVTX-008, has now entered IND-enabling studies, with a target IND submission date of

AVTX

4 minute read

Ironwood Pharmaceuticals Reports Positive Topline Data From Phase III Trial Of LINZESS (linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation; Study Met Primary And Secondary Endpoints

By Bill Haddad

September 6, 7:04 AM

– Study met primary and secondary endpoints – – Results add to body of data supporting the safety of linaclotide for this patient population – – There are currently no FDA approved

IRWD

3 minute read

News

Cardinal Health Adds Four New Independent Directors To Board And Forms New Business Review Committee To Evaluate Portfolio And Operations

By Bill Haddad

September 6, 6:56 AM

Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio, Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced

CAH

2 minute read

News

Liberty Announces Investment In Natron Energy

By Bill Haddad

September 6, 6:51 AM

Liberty Energy Inc. (NYSE:LBRT) announced today an investment in Natron Energy, a global leader in the manufacturing of sodium-ion batteries. Liberty and Natron will collaborate to introduce sodium-ion batteries as an

LBRT

1 minute read

In Case Of Termination Of Merger With Signify Health, Under Certain Circumstances, Signify To Pay Termination Fee Of $228M; If Deal Is Terminated, CVS Required To Pay Signify Health Termination Fee Of $380M Under Certain Specified Circumstances

By Bill Haddad

September 6, 6:21 AM

-Reuters

CVS

4 minute read

Footprint And Gores Holdings VIII Announce Amendments To Merger; Parties Agree To Adjust Pro Forma Enterprise Value Of Footprint From $1.6B Down To $1B; Footprint Secured An Approximately $300 Million Standby Equity Facility Available Upon Closing

By Bill Haddad

September 6, 6:17 AM

Footprint continues to perform strongly with continued revenue growth and robust capacity expansion year-to-date Company secures approximately $300 million standby equity facility available upon the closing

GIIXU

3 minute read

Mannkind Completes Phase 1 Study of Inhaled Clofazimine; Says ‘Study supports the dosing regimen that will be pursued in further clinical programs’

By Bill Haddad

September 6, 6:15 AM

Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical

MNKD

1 minute read

LightInTheBox Holding Q2 EPS $(0.02) Down From $0.08 YoY, Sales $132.40M Beat $78.49M Estimate

By Bill Haddad

September 6, 6:13 AM

LightInTheBox Holding (NYSE:LITB) reported quarterly losses of $(0.02) per share. This is a 125 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of

LITB

1 minute read

Panbela Therapeutics Inc Files For Public Offering Of 28.9M Shares Of Common Stock And Common Stock Purchase Warrants

By Bill Haddad

September 6, 6:10 AM

-Reuters

PBLA

1 minute read

IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

By Bill Haddad

September 6, 6:04 AM

- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear Hospital, Melbourne - Preliminary signals of clinical activity

IDYA